Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Abiraterone + AMG 160 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 160 | HLE-BiTE AMG 160|AMG-160|AMG160|Acapatamab | PSMA Antibody 20 | AMG 160 is a bi-specific T-cell engager (BiTE) antibody that binds to PSMA and CD3, potentially resulting in enhanced T-cell response and antitumor activity against PSMA-expressing tumor cells (PMID: 33504551). | |
Abiraterone | Zytiga | CB7630 | Hormone - Anti-androgens 54 | Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04631601 | Phase I | AMG 160 + AMG 404 AMG 160 + Enzalutamide Abiraterone + AMG 160 AMG 404 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | Terminated | USA | SWE | GBR | ESP | DNK | AUS | 0 |